Last reviewed · How we verify
Mupirocin + Chlorhexidin
Mupirocin + Chlorhexidin is a Topical antibiotic combination Small molecule drug developed by B. Braun Medical SA. It is currently FDA-approved for Wound care and infection prevention, Skin and soft tissue infections, Catheter site care and antisepsis.
Mupirocin inhibits bacterial protein synthesis while chlorhexidine disrupts bacterial cell membranes, providing broad-spectrum antimicrobial activity.
Mupirocin is a small molecule inhibitor of isoleucyl-tRNA synthetase, classified as an INHIBITOR drug class. It is used to treat Staphylococcus Aureus, Methicillin-Resistant Staphylococcus Aureus, and Staphylococcal Skin Infections, among other conditions.
At a glance
| Generic name | Mupirocin + Chlorhexidin |
|---|---|
| Sponsor | B. Braun Medical SA |
| Drug class | Topical antibiotic combination |
| Target | Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
Mupirocin is a topical antibiotic that inhibits isoleucyl-tRNA synthetase, preventing bacterial protein synthesis. Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins. Together, they provide synergistic antimicrobial coverage against gram-positive and gram-negative bacteria, commonly used in wound care and infection prevention.
Approved indications
- Wound care and infection prevention
- Skin and soft tissue infections
- Catheter site care and antisepsis
Common side effects
- Local skin irritation
- Contact dermatitis
- Burning or stinging at application site
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients
- Staph Intervention for Effective Local Defense (PHASE4)
- Bacterial Decolonization Within Dyads (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mupirocin + Chlorhexidin CI brief — competitive landscape report
- Mupirocin + Chlorhexidin updates RSS · CI watch RSS
- B. Braun Medical SA portfolio CI
Frequently asked questions about Mupirocin + Chlorhexidin
What is Mupirocin + Chlorhexidin?
How does Mupirocin + Chlorhexidin work?
What is Mupirocin + Chlorhexidin used for?
Who makes Mupirocin + Chlorhexidin?
What drug class is Mupirocin + Chlorhexidin in?
What development phase is Mupirocin + Chlorhexidin in?
What are the side effects of Mupirocin + Chlorhexidin?
What does Mupirocin + Chlorhexidin target?
Related
- Drug class: All Topical antibiotic combination drugs
- Target: All drugs targeting Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
- Manufacturer: B. Braun Medical SA — full pipeline
- Therapeutic area: All drugs in Dermatology / Infection Prevention
- Indication: Drugs for Wound care and infection prevention
- Indication: Drugs for Skin and soft tissue infections
- Indication: Drugs for Catheter site care and antisepsis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing